Madrigal Pharmaceuticals, Inc.
MDGL
Hisse Senetlerindeki Sıralama
#2021
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Hisse Fiyatı
$446.50
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$10.32B
Değişim (1 gün)
-0.72%
Değişim (1 yıl)
1.48%
Ülke
US
Ticaret Madrigal Pharmaceuticals, Inc. (MDGL)
Kategori
Healthcare
Madrigal Pharmaceuticals, Inc. (MDGL) için kazanç
Jun 2026 itibarıyla kazanç TTM: $-325.10M
Madrigal Pharmaceuticals, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-325.10M'dir. 2023 yılında şirket $-373.63M kazanç elde etti, bu 2022 yılındaki $-295.35M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Madrigal Pharmaceuticals, Inc. için kazanç geçmişi 2001 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-325.10M | -30.22% |
| 2024 | $-465.89M | 24.69% |
| 2023 | $-373.63M | 26.50% |
| 2022 | $-295.35M | 22.12% |
| 2021 | $-241.85M | 19.58% |
| 2020 | $-202.24M | 140.92% |
| 2019 | $-83.95M | 155.85% |
| 2018 | $-32.81M | 5.32% |
| 2017 | $-31.15M | 18.06% |
| 2016 | $-26.39M | -61.57% |
| 2015 | $-68.67M | -20.30% |
| 2014 | $-86.16M | -4.47% |
| 2013 | $-90.19M | 43.64% |
| 2012 | $-62.79M | 32.52% |
| 2011 | $-47.38M | 26.46% |
| 2010 | $-37.47M | -147.37% |
| 2009 | $79.09M | -185.39% |
| 2008 | $-92.62M | 45.87% |
| 2007 | $-63.50M | 7.38% |
| 2006 | $-59.13M | -14.14% |
| 2005 | $-68.86M | 49.92% |
| 2004 | $-45.93M | 64.77% |
| 2003 | $-27.88M | -48.71% |
| 2002 | $-54.35M | 0.00% |
| 2001 | 0.00 | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -1,722.57% |
US
|
|
| $-3.09B | 849.57% |
US
|
|
| $-4.02B | 1,135.39% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -700.02% |
NL
|
